TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36209432

Group type: EXPERIMENTAL
Intervention: Fluoroscopy-guided manual lymph drainage (MLD)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Traditional manual lymph drainage (MLD)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Placebo manual lymph drainage (MLD)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Decongestive lymphatic therapy (DLT)
Number of subjects: 194
Study: 36209441

Group type: EXPERIMENTAL
Intervention: FIL200 mg
Number of subjects: 1755

Group type: EXPERIMENTAL
Intervention: FIL100 mg
Number of subjects: 1755

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1755

Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 1755

Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 1755
Study: 36209795

Group type: EXPERIMENTAL
Intervention: Task-related functional connectivity in language processing
Number of subjects: 150
Study: 36210252

Group type: EXPERIMENTAL
Intervention: Altruism-tailored educational intervention (spoken and written communication) highlighting altruistic benefits of accepting the seasonal influenza vaccine.
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Altruism-tailored communication approach
Number of subjects: 73
Study: 36210299

Group type: EXPERIMENTAL
Intervention: sEphB4-HSA 1000 mg IV administered every 2 weeks, extending to 3 weeks starting from cycle 7
Number of subjects: 14
Study: 36210362

Group type: EXPERIMENTAL
Intervention: Alpha blockade followed by curative surgery
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Alpha blockade
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Curative surgery
Number of subjects: 35
Study: 36210430

Group type: EXPERIMENTAL
Intervention: Self-reported high levels of mental distress
Number of subjects: 553

Group type: COMPARATOR
Intervention: Self-reported low levels of mental distress
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: High levels of mental distress (regardless of diagnosis)
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: High levels of mental distress
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Patients with one or more psychological diagnosis
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: High CORE-10 score and high number of consultations
Number of subjects: 553
Study: 36210483

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36210487

Group type: EXPERIMENTAL
Intervention: Avelumab 10mg/kg IV every 2 weeks while remaining on the same NHTs (abiraterone acetate or enzalutamide)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Avelumab
Number of subjects: 8
Study: 36210799

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36211411

Group type: EXPERIMENTAL
Intervention: Maternal serum IgG and breast milk IgG and IgA antibody titres
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Sera IgG titres at 7-months of age
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Similarities between maternal and cord IgG titres
Number of subjects: 85
Study: 36211530

Group type: EXPERIMENTAL
Intervention: Self-guided, web-based positive affect regulation skills (PARK) delivered over 6 weeks.
Number of subjects: 0
Study: 36211552

Group type: EXPERIMENTAL
Intervention: Supervised exercise program (3 months)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Adjuvant trastuzumab without exercise (Control Group - CG)
Number of subjects: 89
Study: 36211588

Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitor (alirocumab)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 160
Study: 36211703

Group type: EXPERIMENTAL
Intervention: Dinosaur Augmented Reality photo-taking (2018)
Number of subjects: 1915

Group type: EXPERIMENTAL
Intervention: Sit-and-Stand fitness challenge (2019)
Number of subjects: 1915
Study: 36211795

Group type: EXPERIMENTAL
Intervention: Stepped-care programme (care as usual plus guided self-help stress management and cognitive behavioural intervention)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Care as usual only
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Stepped-care programme
Number of subjects: 212
Study: 36211944

Group type: EXPERIMENTAL
Intervention: Ad libitum drinking of a cool sport drink (237 mL every 15-20 min)
Number of subjects: 0
Study: 36212225

Group type: EXPERIMENTAL
Intervention: Mindfulness for Interdisciplinary Health Care Professionals (MIHP)
Number of subjects: 35
Study: 36212504

Group type: EXPERIMENTAL
Intervention: HAI of oxaliplatin plus raltitrexed (TOMOX)
Number of subjects: 113

Group type: COMPARATOR
Intervention: HAI of oxaliplatin plus 5-fluorouracil (FOLFOX)
Number of subjects: 113
Study: 36212557

Group type: EXPERIMENTAL
Intervention: Interactive multimedia educational and consent platform (EngagedMD-EMD)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Standard fertility counseling (conventional group)
Number of subjects: 86
Study: 36212638

Group type: EXPERIMENTAL
Intervention: Interactive web-based programme on relapse management
Number of subjects: 17
Study: 36212652

Group type: EXPERIMENTAL
Intervention: Transcranial alternating current stimulation (tACS) combined with sound stimulation
Number of subjects: 1

Group type: COMPARATOR
Intervention: Aricept and Sodium Oligomannate (previous treatments)
Number of subjects: 1
Study: 36212980

Group type: EXPERIMENTAL
Intervention: Intravesical Ty21a treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard BCG treatment
Number of subjects: 0
Study: 36213913

Group type: EXPERIMENTAL
Intervention: Isha Kriya meditation practice, performed daily for 6 weeks.
Number of subjects: 259
Study: 36214004

Group type: EXPERIMENTAL
Intervention: 4000L alglucosidase alfa for 52 weeks
Number of subjects: 90
Study: 36214051

Group type: EXPERIMENTAL
Intervention: ACTIVE trial (NCT00413218)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: APX001-201 trial (NCT03604705)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: ReSTORE trial (NCT03667690)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Overall non-enrolment
Number of subjects: 256
Study: 36214090

Group type: EXPERIMENTAL
Intervention: Dasatinib plus Peg-IFN-α2b
Number of subjects: 79

Group type: COMPARATOR
Intervention: Dasatinib
Number of subjects: 79

Group type: COMPARATOR
Intervention: Peg-IFN-α2b
Number of subjects: 79
Study: 36214123

Group type: EXPERIMENTAL
Intervention: Heart Transplantation (HT) without pretransplant mechanical circulatory support (MCS)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Heart Transplantation (HT) with pretransplant mechanical circulatory support (MCS)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Long-term Mechanical Circulatory Support (MCS)
Number of subjects: 305
Study: 36214207

Group type: EXPERIMENTAL
Intervention: Collective leadership interventions
Number of subjects: 955
Study: 36214278

Group type: EXPERIMENTAL
Intervention: Eating disorders (ED) treatment
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Personality disorders (PD) assessment
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Baseline levels of borderline PD
Number of subjects: 62
Study: 36214450

Group type: EXPERIMENTAL
Intervention: Endosutured aneurysm repair (ESAR)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Standard endovascular aneurysm repair (sEVAR)
Number of subjects: 192
Study: 36214614

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) treatment
Number of subjects: 39
Study: 36214650

Group type: EXPERIMENTAL
Intervention: Dynamic splinting
Number of subjects: 576
Study: 36214786

Group type: EXPERIMENTAL
Intervention: Proteomic assay based on proximal liquid biopsy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Uterine lavage
Number of subjects: 90
Study: 36214883

Group type: EXPERIMENTAL
Intervention: Saxagliptin
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sildenafil
Number of subjects: 18
Study: 36215056

Group type: EXPERIMENTAL
Intervention: Intact limbs of traumatic unilateral transtibial amputees
Number of subjects: 36

Group type: COMPARATOR
Intervention: Talar cartilage thickness
Number of subjects: 36

Group type: COMPARATOR
Intervention: GCL muscle thickness
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: TA and GCM muscle thicknesses
Number of subjects: 36
Study: 36215065

Group type: EXPERIMENTAL
Intervention: Less intense treatment for breast cancer
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Extrapolation of trial outcomes to underrepresented populations
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Factors influencing comfort in extrapolation
Number of subjects: 39
Study: 36215115

Group type: EXPERIMENTAL
Intervention: Color flow Doppler ultrasound with 1 mL normal saline injection
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Color flow Doppler ultrasound with 1 mL air/saline mixture
Number of subjects: 40
Study: 36215125

Group type: EXPERIMENTAL
Intervention: Bazedoxifene plus palbociclib
Number of subjects: 36
Study: 36215171

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0
Study: 36215217

Group type: EXPERIMENTAL
Intervention: Carfilzomib combined with vincristine, dexamethasone, asparaginase, and daunorubicin (VXLD)
Number of subjects: 24
Study: 36215232

Group type: EXPERIMENTAL
Intervention: Subcutaneous infusion of 235 ml isotonic saline containing a technetium-99m pertechnetate tracer
Number of subjects: 6
Study: 36215912

Group type: COMPARATOR
Intervention: Normative Improvement class
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: High Drug Use class
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: High Recurrence class
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: High Criminogenic Thinking class
Number of subjects: 341
Study: 36215980

Group type: EXPERIMENTAL
Intervention: Loss to follow-up (LTFU)
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Incomplete visit coverage
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Late visits
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Previous late visits
Number of subjects: 813
Study: 36215989

Group type: EXPERIMENTAL
Intervention: Ciltacabtagene autoleucel (cilta-cel) infusion
Number of subjects: 68
Study: 36216013

Group type: EXPERIMENTAL
Intervention: Two doses of BNT162b2
Number of subjects: 16994

Group type: EXPERIMENTAL
Intervention: Three doses of BNT162b2
Number of subjects: 16994

Group type: EXPERIMENTAL
Intervention: Three doses of BNT162b2 (less than 3 months after third dose)
Number of subjects: 16994

Group type: EXPERIMENTAL
Intervention: Three doses of BNT162b2 (3 months or more after third dose)
Number of subjects: 16994
Study: 36216266

Group type: EXPERIMENTAL
Intervention: Intensive endoscopic removal for downstaging of polyp burden (IDP)
Number of subjects: 222
Study: 36216431

Group type: EXPERIMENTAL
Intervention: WeFlow-Arch modular inner branch stent-graft system
Number of subjects: 80
Study: 36216842

Group type: EXPERIMENTAL
Intervention: Abnl-GT-β-cell-failure
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Abnl-GT-IR
Number of subjects: 450
Study: 36216961

Group type: EXPERIMENTAL
Intervention: COVID-HIGIV
Number of subjects: 0

Group type: COMPARATOR
Intervention: PBS (control)
Number of subjects: 0
Study: 36217101

Group type: EXPERIMENTAL
Intervention: HSK3486 (IV bolus dose of 0.4 mg/kg and maintenance infusion of 0.4 mg/kg/h)
Number of subjects: 24

Group type: COMPARATOR
Intervention: HSK3486 (in subjects with mild or moderate hepatic impairment)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal hepatic function subjects
Number of subjects: 24
Study: 36217139

Group type: EXPERIMENTAL
Intervention: Two-dose Gam-COVID-Vac (Sputnik V)
Number of subjects: 23996

Group type: EXPERIMENTAL
Intervention: Three-dose Gam-COVID-Vac (booster)
Number of subjects: 23996

Group type: EXPERIMENTAL
Intervention: EpiVacCorona
Number of subjects: 23996

Group type: EXPERIMENTAL
Intervention: CoviVac
Number of subjects: 23996
Study: 36217526

Group type: EXPERIMENTAL
Intervention: Iptacopan
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 36217600

Group type: EXPERIMENTAL
Intervention: SMBP-App
Number of subjects: 180

Group type: COMPARATOR
Intervention: SMBP alone
Number of subjects: 180
Study: 36219171

Group type: EXPERIMENTAL
Intervention: Web-based survey regarding knowledge and attitudes towards Barrett's esophagus screening
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Concerns about developing Barrett's esophagus or esophageal adenocarcinoma
Number of subjects: 472

Group type: COMPARATOR
Intervention: Comparison of concerns and barriers between racial groups
Number of subjects: 472
Study: 36219274

Group type: EXPERIMENTAL
Intervention: Osilodrostat; median average dose was 10.6 mg/day (1.1-47.9)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Osilodrostat; median exposure from baseline to study end was 5.4 years (0.04-6.7)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Osilodrostat; long-term follow-up
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Osilodrostat; long-term safety profile
Number of subjects: 19
Study: 36219388

Group type: EXPERIMENTAL
Intervention: Triple inhaled therapy
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Long-acting β2-agonists (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combination (FDC)
Number of subjects: 566

Group type: COMPARATOR
Intervention: Circadian rhythm of symptoms
Number of subjects: 566

Group type: COMPARATOR
Intervention: Symptom control
Number of subjects: 566
Study: 36219586

Group type: EXPERIMENTAL
Intervention: Machine learning-based classifier combining multiple cellular and plasma biomarkers with clinical factors.
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Decreases in regulatory natural killer cells, naïve CD4 T helper cells, and naïve regulatory T cells; elevated levels of CXCL9, CXCL10, CXCL11, ST2, ICAM-1, and soluble CD13 (sCD13).
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: sCD13, ST2, and ICAM-1 levels.
Number of subjects: 302
Study: 36219705

Group type: EXPERIMENTAL
Intervention: 3 doses of sulfadoxine-pyrimethamine
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: 3 doses of dihydroartemisinin-piperaquine (DP)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Monthly DP during pregnancy
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: DP every 3 months
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Monthly DP from 2 to 24 months of age
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: More effective malaria chemoprevention
Number of subjects: 305

Group type: COMPARATOR
Intervention: Malaria in pregnancy
Number of subjects: 305
Study: 36220152

Group type: EXPERIMENTAL
Intervention: Once-weekly 300 mg marstacimab
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Once-weekly 150 mg marstacimab (after a 300 mg loading dose)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 20
Study: 36220196

Group type: EXPERIMENTAL
Intervention: Insulin resistance assessed by the insulin sensitivity index (ISI)
Number of subjects: 2752
Study: 36220315

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness assessment in children and adolescents with IBD
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Physical fitness components assessment (muscular strength, speed/agility, flexibility) in children and adolescents with IBD
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cardiovascular risk assessment in adulthood based on physical fitness levels
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Quality of life and daily physical activity assessment in children and adolescents with IBD
Number of subjects: 50
Study: 36220579

Group type: EXPERIMENTAL
Intervention: Conventional decomposition strategy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reclassifying fully mediated interaction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isolating fully mediated interaction
Number of subjects: 0
Study: 36220750

Group type: EXPERIMENTAL
Intervention: Bacterial vector therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bacterial-derived delivery strategies
Number of subjects: 0
Study: 36220852

Group type: EXPERIMENTAL
Intervention: Palbociclib plus aromatase inhibitor (AI)
Number of subjects: 2888

Group type: COMPARATOR
Intervention: Aromatase inhibitor (AI) alone
Number of subjects: 2888
Study: 36220881

Group type: EXPERIMENTAL
Intervention: Hetrombopag
Number of subjects: 35
Study: 36221816

Group type: EXPERIMENTAL
Intervention: AYAC
Number of subjects: 74

Group type: COMPARATOR
Intervention: HC
Number of subjects: 74
Study: 36221952

Group type: EXPERIMENTAL
Intervention: FOLFIRINOX chemotherapy followed by gemcitabine-based chemoradiation
Number of subjects: 22
Study: 36222756

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 458

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 458
Study: 36222789

Group type: EXPERIMENTAL
Intervention: Angiogenic factors classification (soluble fms-like tyrosine kinase to placental growth factor ratio ≥38)
Number of subjects: 1030

Group type: COMPARATOR
Intervention: Standard Doppler-based management
Number of subjects: 1030
Study: 36222801

Group type: EXPERIMENTAL
Intervention: Predictive model development using biomedical and psychosocial variables collected via Noona Healthcare platform, measured every 3 months from presurgery to 18 months post-surgery.
Number of subjects: 660
Study: 36222806

Group type: EXPERIMENTAL
Intervention: Interactive GDM prototype app with features such as automatic personalized suggestions and social support.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interactive GDM prototype app
Number of subjects: 0
Study: 36222818

Group type: EXPERIMENTAL
Intervention: Financial incentives delivered through a mobile app (US $15 biweekly payments, US $2 penalties for missed check-ins)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Financial incentives delivered through a mobile app
Number of subjects: 25
Study: 36222826

Group type: EXPERIMENTAL
Intervention: iRaPID program (integrated rapid access to HIV prevention program)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 50
Study: 36222855

Group type: EXPERIMENTAL
Intervention: SUVmax-FAPI
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: GTV
Number of subjects: 34
Study: 36223060

Group type: EXPERIMENTAL
Intervention: Calcipotriol 0.005% plus Betamethasone Dipropionate 0.064% (Cal/BD) foam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Halobetasol Proprionate 0.01% plus Tazarotene 0.045% (HP/Taz) lotion
Number of subjects: 0
Study: 36223197

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 36223228

Group type: EXPERIMENTAL
Intervention: ACM-Beta spike vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: ACM-WT spike vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) immunization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intranasal (IN) immunization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACM-polymersome-based Covid-19 vaccine
Number of subjects: 0
Study: 36223234

Group type: EXPERIMENTAL
Intervention: Norovirus infection (GII)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Symptomatic norovirus infection
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Healthcare utilization for symptomatic episodes
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Initial infections vs subsequent infections
Number of subjects: 158
Study: 36223547

Group type: EXPERIMENTAL
Intervention: Tinengotinib (TT-00420)
Number of subjects: 0
Study: 36223558

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study: 36223740

Group type: EXPERIMENTAL
Intervention: PARP inhibitor olaparib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of CD47 antibodies and olaparib
Number of subjects: 0
Study: 36223780

Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging pre-processing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no pre-processing)
Number of subjects: 0
Study: 36223961

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) - single intravenous infusion of 375 mg/m²
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standardised corticosteroid treatment
Number of subjects: 44
Study: 36224176

Group type: EXPERIMENTAL
Intervention: Pembrolizumab, trastuzumab, and doublet chemotherapy
Number of subjects: 43
Study: 36224398

Group type: EXPERIMENTAL
Intervention: Somatic manoeuvres (six neck manoeuvres: flexion, extension, lateroflexion left/right, traction and compression; three jaw manoeuvres: protrusion, laterotrusion left/right; one placebo manoeuvre: hand on head)
Number of subjects: 18
Study: 36224595

Group type: EXPERIMENTAL
Intervention: XGBoost nonlinear regression prediction model
Number of subjects: 249
Study: 36225250

Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 84

Group type: COMPARATOR
Intervention: Ephedrine
Number of subjects: 84
Study: 36225342

Group type: EXPERIMENTAL
Intervention: NSTE-MINOCA
Number of subjects: 110

Group type: COMPARATOR
Intervention: NSTE-MI-CAD
Number of subjects: 110
Study: 36225538

Group type: EXPERIMENTAL
Intervention: Food insecurity levels
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Anthropometrics, fasting blood samples, non-blood biomarkers, 24-hour food recall
Number of subjects: 500
Study: 36226495

Group type: EXPERIMENTAL
Intervention: Mivavotinib (TAK-659) 140 mg QD
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Mivavotinib (TAK-659) 60 mg BID
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Mivavotinib (TAK-659)
Number of subjects: 43
Study: 36227183

Group type: EXPERIMENTAL
Intervention: Neurolocate (Renishaw)
Number of subjects: 23
Study: 36227203

Group type: EXPERIMENTAL
Intervention: n-of-1 trials using ambulatory BP monitoring
Number of subjects: 49

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 49
Study: 36227531

Group type: EXPERIMENTAL
Intervention: PROFAD-SSI-SF
Number of subjects: 46
Study: 36227606

Group type: EXPERIMENTAL
Intervention: Bipolar cell transgene RS1 expression using MiniPromoter (Ple155)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bipolar cell transgene RS1 expression using mini-mGluR6 promoter
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no RS1 expression)
Number of subjects: 0
Study: 36227718

Group type: EXPERIMENTAL
Intervention: Intensive SBP control (goal SBP <120 mm Hg)
Number of subjects: 1430

Group type: COMPARATOR
Intervention: Standard SBP control (goal SBP <140 mm Hg)
Number of subjects: 1430
Study: 36227771

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0